Galectin Therapeutics
GALT
69 hedge funds and large institutions have $35.5M invested in Galectin Therapeutics in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 11 closing their positions.
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
50% more capital invested
Capital invested by funds: $23.6M → $35.5M (+$11.8M)
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
11% more funds holding
Funds holding: 62 → 69 (+7)
0.79% more ownership
Funds ownership: 13.99% → 14.78% (+0.79%)
69% less call options, than puts
Call options by funds: $1.17M | Put options by funds: $3.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.91M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.48M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$503K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$368K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$630K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$491K |
| 3 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$481K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$364K |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$305K |
GALT Hedge Fund Activity: Q2 2018 in Review
69 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2018, worth a combined $35.5M — up 50% from $23.6M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GALT positions and 11 closed out — a net gain of 7 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $1.91M. The largest seller was Sabby Management, cutting an estimated $630K.
- 69 institutional investors held Galectin Therapeutics (GALT) as of Q2 2018, up from 62 in Q1 2018.
- Funds reported $35.5M of Galectin Therapeutics stock for Q2 2018, up 50% quarter-over-quarter.
- 18 funds opened new Galectin Therapeutics positions in Q2 2018 and 11 closed out, a net change of +7 holders.
- The largest Galectin Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.91M added.
- The largest Galectin Therapeutics seller in Q2 2018 was Sabby Management, an estimated $630K sold.
Based on aggregated 13F filings for Q2 2018.